Frederic Bibeau

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
  2. ncbi request reprint [Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, Montpellier
    Gastroenterol Clin Biol 30:611-3. 2006
  3. doi request reprint [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view]
    F Bibeau
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Service de Pathologie, 34298 Montpellier Cedex 05, France
    Bull Cancer 96:S15-22. 2009
  4. ncbi request reprint Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 208 Rue des Apothicaires, Montpellier Cedex 5, France
    Virchows Arch 452:103-7. 2008
  5. ncbi request reprint [An unusual liver metastasis]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, Cedex 5
    Ann Pathol 26:455-6. 2006
  6. doi request reprint [Management of colorectal liver metastases after induction treatment. The pathologist's role in 2011]
    Frederic Bibeau
    Service de Pathologie, CRLC C Val d Aurelle, Montpellier Cedex, France
    Ann Pathol 31:427-32. 2011
  7. pmc Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 34298, Montpellier, Cedex 5, France
    Virchows Arch 449:281-7. 2006
  8. ncbi request reprint Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
    Frederic Bibeau
    Departement de Pathologie, Centre régional de lutte contre le cancer Val d Aurelle Paul Lamarque, 208 Rue des Apothicaires, Parc Euromedecine, 34298 Montpellier Cedex 05 France
    J Clin Oncol 27:1122-9. 2009
  9. ncbi request reprint [Management of non-palpable breast lesions with vacuum-assisted large core needle biopsies (Mammotome). Experience with 560 procedures at the Val d'Aurelle Center]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRCL Val d Aurelle, Montpellier
    Ann Pathol 23:582-92. 2003
  10. ncbi request reprint [Recent data on lobular neoplasia of the breast: the pathologist's opinion]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, 208, rue des Apothicaires, 34298 Montpellier Cedex
    Bull Cancer 92:453-8. 2005

Detail Information

Publications50

  1. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
    ....
  2. ncbi request reprint [Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, Montpellier
    Gastroenterol Clin Biol 30:611-3. 2006
    ..Vascular damage may remain histological, as in our case. But one should be aware that vascular injuries could influence hepatic function and regeneration after wide hepatectomy as well as extensive fibrosis...
  3. doi request reprint [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view]
    F Bibeau
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Service de Pathologie, 34298 Montpellier Cedex 05, France
    Bull Cancer 96:S15-22. 2009
    ..Thus, the pathologist may contribute to validate new molecular tests and to offer his specific techniques for translational research...
  4. ncbi request reprint Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 208 Rue des Apothicaires, Montpellier Cedex 5, France
    Virchows Arch 452:103-7. 2008
    ..Moreover, it is particular because of its favourable behaviour, with a 6-year disease-free survival, after neoadjuvant chemoradiation, surgery and postoperative chemotherapy...
  5. ncbi request reprint [An unusual liver metastasis]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, Cedex 5
    Ann Pathol 26:455-6. 2006
  6. doi request reprint [Management of colorectal liver metastases after induction treatment. The pathologist's role in 2011]
    Frederic Bibeau
    Service de Pathologie, CRLC C Val d Aurelle, Montpellier Cedex, France
    Ann Pathol 31:427-32. 2011
    ..Moreover, the determination of predictive markers of response or resistance to induction treatments will constitute a supplementary and major challenge for the pathologist...
  7. pmc Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 34298, Montpellier, Cedex 5, France
    Virchows Arch 449:281-7. 2006
    ..In conclusion, EGFR expression measured in tissue sections from primary CRC and their related metastases was found to be similar and frequent, but it was significantly underestimated by the TMA technique...
  8. ncbi request reprint Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
    Frederic Bibeau
    Departement de Pathologie, Centre régional de lutte contre le cancer Val d Aurelle Paul Lamarque, 208 Rue des Apothicaires, Parc Euromedecine, 34298 Montpellier Cedex 05 France
    J Clin Oncol 27:1122-9. 2009
    ..We investigated the association of FcgammaR polymorphisms and KRAS mutation with the outcome of irinotecan-refractory mCRC patients treated with cetuximab plus irinotecan...
  9. ncbi request reprint [Management of non-palpable breast lesions with vacuum-assisted large core needle biopsies (Mammotome). Experience with 560 procedures at the Val d'Aurelle Center]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRCL Val d Aurelle, Montpellier
    Ann Pathol 23:582-92. 2003
    ..This procedure should be based on a multidisciplinary approach and dialog...
  10. ncbi request reprint [Recent data on lobular neoplasia of the breast: the pathologist's opinion]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, 208, rue des Apothicaires, 34298 Montpellier Cedex
    Bull Cancer 92:453-8. 2005
    ..They should be managed in a pluridisciplinar way and correctly diagnosed on percutaneous biopsies as well as surgical specimens...
  11. doi request reprint KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment
    Florence Boissière-Michot
    Department of Pathology, Val d Aurelle Cancer Institute, Montpellier, France
    Mod Pathol 25:731-9. 2012
    ..The use of more sensitive assays, such as allele-specific PCR or laser microdissection, can be envisaged but with higher costs and longer delays...
  12. doi request reprint [Locally advanced rectal cancer management: which role for the pathologist in 2011?]
    Frederic Bibeau
    Service de Pathologie, CRLC Val d Aurelle, Montpellier, France
    Ann Pathol 31:433-41. 2011
    ....
  13. doi request reprint Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas
    Virginie Granci
    Institut de Recherche en Cancérologie de Montpellier IRCM, INSERM, U896, Université Montpellier1, CRLC Val d Aurelle Paul Lamarque, 208 Rue des Apothicaires, F 34298 Montpellier Cedex 5, France
    Eur J Cancer 44:2312-8. 2008
    ..1 in the good prognostic group. Thus, the combination of TRAIL-R1 and TRAIL-R3 expression might represent a predictive and prognostic factor of the response to 5-FU-based first-line chemotherapy in patients with metastatic CRC...
  14. pmc Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization
    Alexandre Ho-Pun-Cheung
    INSERM U, Val d Aurelle Cancer Institute, Montpellier, France
    BMC Mol Biol 10:31. 2009
    ..Normalization to accurately quantitated RNA has been proposed as the most reliable method for in vivo biopsies. However, this approach does not correct differences in RNA integrity...
  15. doi request reprint The non-crosslinking fixative RCL2®-CS100 is compatible with both pathology diagnosis and molecular analyses
    Florence Boissière-Michot
    Department of Pathology, Val d Aurelle Cancer Institute, Montpellier 34 298, France
    Pathol Oncol Res 19:41-53. 2013
    ..However, specific procedures for tissue handing and processing, essential to provide high-quality specimens, could limit its use to small target lesions which cannot be frozen without impairing their pathological evaluation...
  16. doi request reprint [Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment]
    Frederic Bibeau
    CRLC Val d Aurelle, Service de Pathologie, Parc Euromedecine, Montpellier, France
    Bull Cancer 99:743-51. 2012
    ..This study also underlines the broad spectrum of genotyping techniques (no consensus). The delays of response are still longer than expected but might be improved by optimizing the procedures...
  17. pmc Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial
    Eric Assenat
    CAC Val d Aurelle, Montpellier, France
    Oncologist 16:1557-64. 2011
    ....
  18. pmc Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer
    David Azria
    Department of Radiation Oncology, Val d Aurelle Cancer Institute, Montpellier, France
    BMC Cancer 5:62. 2005
    ..We wished to ascertain whether a correlation exists between the expression of EGFR and treatment outcome in a group of patients with rectal adenocarcinoma who had undergone preoperative radiotherapy (RT)...
  19. doi request reprint EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer
    Alexandre Ho-Pun-Cheung
    Department of Biology, Val d Aurelle Cancer Institute, Montpellier, France
    Int J Cancer 128:2938-46. 2011
    ..011) remained independent prognostic factors for distant metastasis. In conclusion, quantification of EGFR and HER3 mRNA expression in pretreatment biopsies may be useful to identify patients who are at risk of developing metastases...
  20. pmc Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan
    Maguy Del Rio
    Centre National de la Recherche Scientifique Unité Mixte de Recherche 5160, Service d Anatomie Pathologique, Service d Oncologie Digestive, Montpellier, France
    J Clin Oncol 25:773-80. 2007
    ..A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response...
  21. doi request reprint MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy
    Stephanie Nougaret
    Department of Abdominal Imaging, Saint Eloi University Hospital, Montpellier, France
    Radiology 263:409-18. 2012
    ....
  22. ncbi request reprint BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
    William Jacot
    Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France
    BMC Cancer 13:523. 2013
    ..However, a comprehensive analysis of PARP-1 activity, BRCA1 promoter methylation and 53BP1 expression in tumours without known BRCA1 mutation has not yet been carried out...
  23. ncbi request reprint Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer
    Alexandre Ho-Pun-Cheung
    INSERM U860, and Department of Oncobiology, Val d Aurelle Cancer Institute, 208 Rue des Apothicaires, 34298 Montpellier, France
    Int J Radiat Oncol Biol Phys 68:1094-101. 2007
    ..To investigate whether CCND1 genetic variations associated with a constitutive nuclear protein may influence either the pathologic response to preoperative RT or the prognosis in a series of rectal cancer patients...
  24. doi request reprint Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer
    William Jacot
    CRLC Val d Aurelle, Montpellier, France
    Am J Clin Oncol 33:544-9. 2010
    ..The aim of this study was to evaluate the efficacy and safety profile of 4 dose-dense cycles of docetaxel followed by 3 cycles of FEC100 neoadjuvant chemotherapy in patients with operable advanced breast cancer...
  25. pmc Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer
    Monique Chambon
    Institut de Recherche en Cancérologie de Montpellier IRCM, Montpellier, France Inserm U896, Montpellier, France
    Am J Pathol 178:1461-9. 2011
    ....
  26. doi request reprint An alternative fixative to formalin fixation for molecular applications: the RCL2(®)-CS100 approach
    Amélie Denouel
    CRLC Val d Aurelle, Montpellier, France
    Methods Mol Biol 724:297-307. 2011
    ..We adapted RCL2 tissue fixation protocol so it could be used on a routine and automated laboratory basis, still preserving its good performances. This protocol will be described in detail in the following review...
  27. ncbi request reprint Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 63011 Clermont Ferrand Cedex, France
    Oncol Rep 16:1173-9. 2006
    ..No scoring system showed, to date, its accuracy, and more studies have to be conducted with an evaluation of the response to cetuximab, possibly with a correlation with FISH amplification in colorectal carcinoma...
  28. doi request reprint [Hormone receptors and HER-2 changes during breast cancer progression: clinical implications]
    William Jacot
    CRLC Val d Aurelle, Service d Oncologie Medicale, Montpellier Cedex, France
    Bull Cancer 98:1059-70. 2011
    ..This article presents a comprehensive analysis of the frequency of theses phenotypic changes altogether with new modalities to evaluate this phenotypic status...
  29. ncbi request reprint Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
    Alain R Thierry
    1 U896 INSERM, Institut Recherche en Cancérologie de Montpellier, Montpellier, France 2 Sysdiag UMR3145 CNRS, CAP DELTA, Montpellier, France
    Nat Med 20:430-5. 2014
    ..CfDNA was detected in 100% of patients with mCRC. This study shows that liquid biopsy through cfDNA analysis could advantageously replace tumor-section analysis and expand the scope of personalized medicine for patients with cancer. ..
  30. doi request reprint Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer
    Haïdar Saadoun
    Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France
    Future Oncol 10:195-209. 2014
    ..Following the introduction of new adjuvant therapies we wanted to reappraise the prognostic and predictive value of uPA/PAI-1 in early breast cancer...
  31. ncbi request reprint Snail and slug play distinct roles during breast carcinoma progression
    Christophe Come
    EMI229 Institut National de la Sante et de la Recherche Medicale, Genotypes et Phenotypes Tumoraux, Centre de Recherche en Cancerologie, CRLC Val d Aurelle Paul Lamarque, Montpellier, France
    Clin Cancer Res 12:5395-402. 2006
    ..Here, we investigate the role of Snail and Slug in human breast cancer progression...
  32. doi request reprint Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer
    Frederique Penault-Llorca
    Department of Pathology, Centre Jean Perrin, EA 4233, Université d Allvergne Clermont 1, Clermont Ferrand 63000, France
    J Clin Oncol 27:2809-15. 2009
    ..89; 95% CI, 0.47 to 1.66; P = .71). CONCLUSION Ki67 expression identifies a subset of patients with ER-positive breast cancer who could be sensitive to docetaxel treatment in the adjuvant setting...
  33. pmc Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
    William Jacot
    Departement d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, 208, rue des Apothicaires, F 34298, France
    Breast Cancer Res 13:R133. 2011
    ..Because variations in the frequency of EGFR-activating mutations in East Asians and other patients with lung cancer have been described, we evaluated the EGFR mutational profile in tumour samples from European patients with TNBC...
  34. pmc Specific extracellular matrix remodeling signature of colon hepatic metastases
    Maguy Del Rio
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France INSERM, U896, Montpellier, France Université MONTPELLIER1, Montpellier, France ICM, Institut régional du Cancer Montpellier, Montpellier, France
    PLoS ONE 8:e74599. 2013
    ..Because of the high efficiency of the signature to classify colon hepatic metastases, the identified genes represent promising targets to develop new therapies that will specifically affect hepatic metastasis microenvironment. ..
  35. ncbi request reprint [Positive sentinel node biopsy in breast cancer: is axillary surgery necessary in all cases?]
    Frédéric Trentini
    Service de Chirurgie, CRLC Val d Aurelle Paul Lamarque, 208, rue des Apothicaires, Parc Euromedecine, 34298 Montpellier Cedex 5
    Bull Cancer 94:700-4. 2007
    ..Additional axillairy clearing out at the time of a positive node sentinel biopsy should be discussed according to different criteria determined by a precise histological analysis...
  36. ncbi request reprint Assessment of RNA quality extracted from laser-captured tissues using miniaturized capillary electrophoresis
    Virginie Copois
    Unité INSERM 540 and Service de Biologie Cellulaire, Centre Hospitalier Universitaire de Montpellier, Hopital Arnaud de Villeneuve, Montpellier, France
    Lab Invest 83:599-602. 2003
  37. ncbi request reprint Liver metastases in prostate carcinoma: clinical characteristics and outcome
    Damien Pouessel
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    BJU Int 99:807-11. 2007
    ..To assess the clinical characteristics and outcome of patients with liver metastases in prostate carcinoma...
  38. pmc A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study
    Maia Chanrion
    INSERM U868, Cancer Research Centre, CRLC Val d Aurelle Paul Lamarque, Montpellier, France
    BMC Cancer 7:39. 2007
    ..Molecular profiling using a large panel of genes could help to classify breast tumours and to define signatures which are predictive of their clinical behaviour...
  39. pmc Oestrogen receptor negative breast cancers exhibit high cytokine content
    Carine Chavey
    INSERM, U844, Site Saint Eloi, bâtiment INM, University of Montpellier I, rue Augustin Fliche, Montpellier, F 34091, France
    Breast Cancer Res 9:R15. 2007
    ..An emerging hypothesis suggests that cytokines could play an important role in cancer as potential modulators of angiogenesis and leucocyte infiltration...
  40. ncbi request reprint ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases
    Laurent Candeil
    CNRS UMR 5160, Centre de Recherche en Cancerologie, CRLC Val d Aurelle, Montpellier, France
    Int J Cancer 109:848-54. 2004
    ..In conclusion, this study supports the potential involvement of ABCG2 in the development of irinotecan resistance in vivo...
  41. ncbi request reprint Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice
    Christel Larbouret
    INSERM, Centre de Recherche en Cancerologie de Montpellier, Universite de Montpellier, CRLC Val d Aurelle Paul Lamarque, Montpellier, France
    Int J Radiat Oncol Biol Phys 69:1231-7. 2007
    ..We report the evaluation of this strategy in immunocompetent CEA-transgenic mice...
  42. doi request reprint [The design of new protocols/what place for the pathology departments?]
    Frederic Bibeau
    Service de Pathologie, CRLCC Val d Aurelle, 208, rue des Apothicaires, 34298 Montpellier Cedex 5
    Bull Cancer 95:995-1001. 2008
    ..All these subjects are discussed in this review article...
  43. doi request reprint [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 58, rue Montalembert, 63011 Clermont Ferrand, France
    Ann Pathol 30:357-73. 2010
    ..Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs)...
  44. doi request reprint [HER2 and gastric cancer. Recommendations for clinical practice in 2011]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, BP 392, 58, rue Montalembert, 63011 Clermont Ferrand Cedex, France EA 4233, Universite d Auvergne, 63000 Clermont Ferrand Cedex, France
    Ann Pathol 31:78-87. 2011
    ..This will ensure accurate and consistent HER2 testing results, which will allow the appropriate selection of patients eligible for treatment with trastuzumab...
  45. pmc HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort
    Philippe Rouanet
    Montpellier Cancer Institute Val d Aurelle, Montpellier, France
    Cancer Med 3:134-42. 2014
    ..In HER2-positive breast cancers, HR expression is associated with a poor prognosis despite the hormone therapy. For this population, a personalized management may be required...
  46. ncbi request reprint [Image in pathology]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, 208 Rue des Apothicaires, 34298 Montpellier Cedex, France
    Ann Pathol 24:374. 2004
  47. doi request reprint The use of MR imaging in treatment planning for patients with rectal carcinoma: have you checked the "DISTANCE"?
    Stephanie Nougaret
    Department of Imaging, CHU Montpellier, St Eloi hospital, Montpellier France, 80 av Augustin Fliche, 295 Montpellier Cedex 5, France
    Radiology 268:330-44. 2013
    ....
  48. ncbi request reprint Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cells
    Safia Malki
    Department of Development and Differentiation, Institut de Génétique Humaine IGH CNRS UPR1142, 141, rue de la Cardonille, 34396 Montpellier, Cedex 5, France
    Cancer Lett 255:182-93. 2007
    ..Accordingly, as stimulating the PGD2/DP1 signal transduction pathway upregulates SOX9 expression, either activators of this pathway or DP1 agonists may be useful as new therapeutic agents...
  49. ncbi request reprint Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality
    Virginie Copois
    CNRS UMR 5160, CRLC Val d Aurelle, Montpellier, France
    J Biotechnol 127:549-59. 2007
    ..The combination of these methods, allowing monitoring of RNA quality prior to and after the hybridization experiments, ensured reliable and reproducible microarray data...
  50. ncbi request reprint High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study
    Magali Lacroix-Triki
    Department of Pathology, Institut Claudius Regaud, 20 24 rue du Pont saint Pierre, 31052 Toulouse Cedex, France
    Eur J Cancer 42:2946-53. 2006
    ..82). As expected, the score 2+ group showed poor agreement (kappa=0.38). A quality assurance process showed that ring studies and adherence to national guidelines greatly improve inter-observer reproducibility...